TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces CleanTag® – a new technology that addresses one of the biggest problems in NGS library preparation – adapter dimer formation. CleanTag’s modified adapters block adapter-adapter formation, which leads to significantly higher quality sequencing data and increases mappable sequencing reads over existing technology. Even with samples containing low-abundance miRNA, such as blood or plasma, CleanTag delivers superior results.
The CleanTag method eliminates the need for gel purification, enabling a workflow that is fully compatible with automation. This is the first time that small RNA library preparation has been automation-friendly. CleanTag is compatible with Illumina and Thermo Fisher Scientific sequencers.
"We are pleased to have resolved some of these NGS library prep challenges,” explains Anton McCaffrey, Ph.D., senior director of R&D for TriLink BioTechnologies. “CleanTag chemistry results in a cleaner process and end product, improving the quality data that can be harvested for the research."
Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of high-quality nucleic acid and mRNA products for research, diagnostics, therapeutics and OEM customers. TriLink BioTechnologies’ products are instrumental in the discovery and development processes in gene and oligonucleotide therapy, nucleoside chemotherapy and diagnostics. The company is ISO 9001 certified and is compliant with ICH Q7, 21 CFR 210 and 21 CFR 820. TriLink BioTechnologies is headquartered in San Diego, Calif., where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.
David Weber, Chief Commercial Officer